• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 5. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Carbazoles

Professional Introduction to 1-Carbazol-9-yl-3-(2-methoxy-ethylamino)-propan-2-ol (CAS No. 436088-68-5)

1-Carbazol-9-yl-3-(2-methoxy-ethylamino)-propan-2-ol, identified by its Chemical Abstracts Service number (CAS No. 436088-68-5), is a compound of significant interest in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to a class of molecules that exhibit promising biological activities, making it a subject of extensive research and development in academic and industrial settings.

The structural framework of 1-carbazol-9-yl-3-(2-methoxy-ethylamino)-propan-2-ol incorporates a carbazole moiety, which is known for its role in various biological processes and its potential as a pharmacophore. The carbazole ring, characterized by its aromaticity and electron-rich nature, is often integrated into drug molecules due to its ability to interact with biological targets such as enzymes and receptors. In this compound, the carbazole moiety is positioned at the 1-position, providing a stable aromatic core that can be further functionalized for enhanced biological activity.

The presence of the 3-(2-methoxy-ethylamino)-propyl side chain in 1-carbazol-9-yl-3-(2-methoxy-ethylamino)-propan-2-ol adds another layer of complexity and functionality to the molecule. The 2-methoxy group within this side chain can influence the compound's solubility, metabolic stability, and interactions with biological targets. This structural feature is particularly noteworthy, as it can be exploited to modulate the pharmacokinetic properties of the compound, thereby improving its therapeutic efficacy.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to gain deeper insights into the interactions between 1-carbazol-9-yl-3-(2-methoxy-ethylamino)-propan-2-ol and its biological targets. These studies have highlighted the potential of this compound as an inhibitor of various enzymes and receptors involved in critical biological pathways. For instance, preliminary computational studies suggest that this molecule may interact with enzymes such as cytochrome P450 isoforms, which are known to play a crucial role in drug metabolism.

In addition to its enzymatic interactions, 1-carbazol-9-yl-3-(2-methoxy-ethylamino)-propan-2-ol has shown promise in modulating signaling pathways associated with inflammation and cancer. The carbazole moiety, in particular, has been implicated in anti-inflammatory effects by interacting with nuclear factor kappa B (NFκB) signaling pathways. This interaction can lead to the suppression of pro-inflammatory cytokine production, thereby reducing inflammation and associated pathologies.

The methoxy group within the side chain also contributes to the compound's potential therapeutic applications. Methoxy-substituted compounds are known to exhibit enhanced bioavailability and metabolic stability, which are critical factors for drug development. The methoxy group can also serve as a site for further chemical modifications, allowing researchers to fine-tune the properties of the molecule for specific therapeutic needs.

Current research in medicinal chemistry focuses on optimizing the structure of 1-carbazol-9-ytlr3-(2-methoxyethylamino)-propanr22-rrol to improve its pharmacological profile. Techniques such as structure-based drug design (SBDD) and fragment-based drug discovery (FBDD) are being employed to identify analogs with enhanced potency, selectivity, and reduced toxicity. These approaches leverage high-throughput screening (HTS) data and computational models to guide the design of novel derivatives.

The synthesis of 1-carbazolr9-ytlr3-(2-methoxyr-r-rlylr-r-r-r-r-r-r-r-r-r-r-r-propanr22rrol

The pharmacokinetic properties of 1-carbazorl9-ytlr3-(2-methoxyr-rlylr-propanr22rrol

In conclusion, 1-carbazorl9-ytlr3-(2-methoxyrlylr-propanr22rrol

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)